Brooklyn Investment Group Acquires 46 Shares of Humana Inc. (NYSE:HUM)

by · The Cerbat Gem

Brooklyn Investment Group lifted its stake in Humana Inc. (NYSE:HUM – Free Report) by 6.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 736 shares of the insurance provider’s stock after purchasing an additional 46 shares during the period. Brooklyn Investment Group’s holdings in Humana were worth $233,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in HUM. FMR LLC grew its stake in Humana by 23.4% in the 3rd quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock worth $1,073,387,000 after acquiring an additional 643,291 shares in the last quarter. Pzena Investment Management LLC raised its stake in shares of Humana by 8.1% during the third quarter. Pzena Investment Management LLC now owns 2,506,250 shares of the insurance provider’s stock valued at $793,830,000 after acquiring an additional 187,903 shares in the last quarter. Davis Selected Advisers boosted its holdings in shares of Humana by 16.1% in the second quarter. Davis Selected Advisers now owns 2,311,362 shares of the insurance provider’s stock valued at $863,640,000 after purchasing an additional 321,233 shares during the period. Marshall Wace LLP grew its stake in Humana by 118.9% in the second quarter. Marshall Wace LLP now owns 1,425,302 shares of the insurance provider’s stock worth $532,564,000 after purchasing an additional 774,085 shares in the last quarter. Finally, Legal & General Group Plc increased its holdings in Humana by 2.1% during the 2nd quarter. Legal & General Group Plc now owns 1,183,985 shares of the insurance provider’s stock worth $442,396,000 after purchasing an additional 24,842 shares during the period. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Stock Down 2.9 %

HUM stock opened at $295.49 on Wednesday. The stock has a market capitalization of $35.58 billion, a PE ratio of 26.17, a price-to-earnings-growth ratio of 2.40 and a beta of 0.52. Humana Inc. has a 52 week low of $213.31 and a 52 week high of $527.18. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67. The firm has a 50 day moving average of $276.28 and a 200 day moving average of $330.23.

Humana (NYSE:HUM – Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, topping the consensus estimate of $3.48 by $0.68. The business had revenue of $29.30 billion during the quarter, compared to the consensus estimate of $28.66 billion. Humana had a net margin of 1.18% and a return on equity of 13.20%. Sell-side analysts forecast that Humana Inc. will post 15.86 earnings per share for the current year.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be issued a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.20%. The ex-dividend date is Tuesday, December 31st. Humana’s dividend payout ratio is presently 31.36%.

Analyst Ratings Changes

Several equities research analysts have weighed in on HUM shares. Sanford C. Bernstein upgraded Humana from a “market perform” rating to an “outperform” rating and set a $308.00 target price for the company in a report on Tuesday, October 8th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $395.00 price objective on shares of Humana in a research note on Tuesday, October 1st. TD Cowen increased their target price on shares of Humana from $261.00 to $268.00 and gave the stock a “hold” rating in a report on Monday, November 4th. Leerink Partners lowered shares of Humana from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $400.00 to $250.00 in a report on Wednesday, October 2nd. Finally, Leerink Partnrs cut shares of Humana from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Twenty research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $315.86.

Check Out Our Latest Research Report on HUM

Humana Profile

(Free Report)

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Stories